PT-141 · Desire and arousal
Four ways to take PT-141. Pick the one that fits your plans.
As low as $199 $119Save 40%12-month plan · billed upfront · vs buy once per month
as low as · choose 1, 3, or 12 months. A clinician reviews your online visit.
The formats
Choose a format here, or use the short format picker in your visit.
Sublingual or buccal mini troche
A small oral dose that dissolves under the tongue or in the cheek.
8 troches · 30-day package
As low as $199 $119Save 40%12-month plan · billed upfront · vs buy once per monthChoose 1, 3, or 12 months
Metered nasal spray
A metered nasal spray in a 3 mL bottle.
3 mL bottle · 30-day package
As low as $299 $199Save 33%12-month plan · billed upfront · vs buy once per monthChoose 1, 3, or 12 months
Sublingual film strip
A thin film that dissolves under the tongue.
24 strips · 30-day package
As low as $239 $149Save 37%12-month plan · billed upfront · vs buy once per monthChoose 1, 3, or 12 months
Sublingual tablet
PT-141 and oxytocin together in a tablet that dissolves under the tongue.
8 tablets · 30-day package
As low as $199 $119Save 40%12-month plan · billed upfront · vs buy once per monthChoose 1, 3, or 12 months
Troches come in 2 mg. Nasal spray comes in 5 mg/mL. PT-141 + oxytocin tablets contain both ingredients.
The guide
Peptides for sexual health are prescription compounds, led by PT-141 (bremelanotide), that act on brain pathways tied to desire and arousal rather than on blood flow.
Peptides are short chains of amino acids that act as signals in the body. Sexual problems are common: in a national U.S. survey of adults aged 18 to 59, 43% of women and 31% of men reported at least one persistent sexual problem. Compounded PT-141 is now prescribed online in needle-free PT-141 formats. A licensed clinician should match the treatment to the specific problem.
Some can, through a different method than the familiar erectile dysfunction (ED) pills. PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) improve the erectile response by increasing blood flow. Some peptides act earlier, on brain signaling behind desire.
Three have published human research in sexual function:
| Peptide | What it targets | Strongest human evidence | FDA status for low desire |
|---|---|---|---|
| PT-141 (bremelanotide) | Melanocortin receptors (MC3R and MC4R) in the brain | Two phase 3 trials in premenopausal women; small early studies in men | Approved as Vyleesi injection for premenopausal women only |
| Kisspeptin | The reproductive hormone axis and sexual brain processing | Small crossover trials using an IV infusion | Not approved |
| Oxytocin | Bonding, orgasm, and post-sex contentment | One small study in healthy couples using a nasal spray | Not approved for sexual function |
Desire depends on a balance between brain systems that excite sexual interest and systems that inhibit it.
A review of the brain pathways of sexual desire describes dopamine systems linking the hypothalamus and limbic system as the core of sexual excitation. Melanocortins, oxytocin, and norepinephrine belong to the same excitatory system. PT-141 works on the melanocortin part of it.
Serotonin, opioid, and endocannabinoid systems become active during sexual inhibition and blunt the excitatory side. Low desire can come from too little excitation, too much inhibition, or both.
Desire and erection are separate steps. Someone with strong interest but unreliable erections has a different problem from someone with good erections and no interest, and each calls for a different treatment.
PT-141, also known as bremelanotide, is the most studied peptide for sexual desire. It is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), and its approved form is Vyleesi.
PT-141 activates melanocortin receptors, specifically MC3R and MC4R, which are found mainly in the central nervous system. These receptors influence pathways tied to sexual motivation and arousal. Unlike PDE5 inhibitors that work downstream on blood vessels, PT-141 acts upstream on the desire circuitry itself.
Each study below names the method it tested. Results from an injection don't automatically apply to a troche, strip, or spray.
| Study | Method tested | Who was studied | Size and length | What it found |
|---|---|---|---|---|
| RECONNECT phase 3 trials (2019) | Injection | Premenopausal women with hypoactive sexual desire disorder (HSDD) | 1,267 women, 24 weeks | Desire scores rose, and distress about low desire fell compared with placebo |
| Intranasal study in men (2004) | Nasal spray | Healthy men and men with mild-to-moderate ED who responded to Viagra | Small, placebo-controlled, in-clinic | Significant erectile response compared with placebo |
| Injection study in men (2004) | Injection | Healthy men and men with an inadequate response to Viagra | Small, placebo-controlled, in-clinic | Significant erectile response, including in men who hadn't responded well to Viagra |
The women's data is the strongest: the RECONNECT trials supported the 2019 FDA approval. The men's data is early, and no phase 3 trial has tested PT-141 in men.
Vyleesi is approved for premenopausal women with acquired, generalized HSDD. Its patient information states that bremelanotide injection should not be used in men or to improve sexual performance.
Compounded PT-141 contains the same molecule, prepared by a pharmacy for an individual prescription. It is not FDA-approved, it doesn't carry Vyleesi's indication, and when a clinician prescribes it for men or in a different format, that is off-label use.
The evidence differs by sex, so the options do too.
Two drugs are FDA-approved for premenopausal women with HSDD: bremelanotide (Vyleesi) and flibanserin (Addyi), a nonhormonal pill that acts on serotonin receptors. Bremelanotide targets desire rather than arousal mechanics, which matches how many women describe low libido.
The RECONNECT trials enrolled only premenopausal women, so the evidence doesn't extend to women after menopause.
For men, PT-141 targets the desire step that PDE5 inhibitors miss. It isn't a testosterone treatment, so a documented hormone problem is a separate conversation with your clinician.
Kisspeptin is the other peptide with data in men. In a 2023 randomized crossover trial of 32 men with HSDD, an IV kisspeptin infusion increased activity in sexual brain regions, increased penile tumescence by up to 56% compared with placebo, and raised reported happiness about sex. It's early research, not a prescription option.
No single peptide is best for every man. The answer depends on which step is failing:
| Situation | What acts on that step | Where PT-141 fits |
|---|---|---|
| Desire is intact, erections are unreliable | PDE5 inhibitors such as sildenafil and tadalafil, which act on the genital response | Not the first choice |
| Desire is low, erections are fine | No licensed drug exists for low desire in men; a clinician checks hormones, medications, sleep, and mood first | The most studied peptide that acts on desire, used off-label |
| Both desire and erections are affected | A clinician-led workup of hormones, heart health, and medications | Sometimes considered alongside ED treatment, with a clinician setting the plan |
For a closer look at the two drug classes, see how PT-141 compares with Viagra and Cialis.
Rebody offers four needle-free PT-141 formats. A licensed clinician reviews your health history and preferences to determine the right prescription format.
| Format | What it is | Strengths and package | Human research on this format |
|---|---|---|---|
| PT-141 troches | A mini sublingual or buccal troche that dissolves under the tongue or in the cheek | 2 mg; 8 troches | None yet |
| PT-141 nasal spray | A metered nasal spray | 5 mg/mL in a 3 mL bottle | Small early intranasal studies in women and men |
| PT-141 strips | A thin film that dissolves under the tongue | 2 mg; 24 strips | None yet |
| PT-141 + oxytocin dissolving tablets | A sublingual tablet with both actives | 1 mg + 20 IU or 2 mg + 40 IU; 8 tablets | Each active studied separately; not the combination |
Your clinician sets your dose and directions. The strength on your label is the only one that applies to you.
You can get PT-141 through a doctor's office or a telehealth platform that prescribes compounded medications after a clinician review.
A clinician-led process looks like this:
Before you start with any provider, ask:
Rebody Health works this way: a licensed clinician reviews every online visit, and the site carries LegitScript certification.
Bremelanotide's side effects are documented in the Vyleesi trials and patient information.
Get urgent care for hives, swelling, trouble breathing, chest tightness, or fainting.
If desire itself has faded, PT-141 is the most studied peptide that acts on it, and Rebody offers it in needle-free formats. A licensed clinician reviews your health history, a pharmacy prepares your prescription with your name and strength on the label, and the care team stays available as you go.
Start an online visitTRT and peptides do different jobs. TRT directly replaces testosterone and is typically used for clinically confirmed low testosterone with symptoms. PT-141 isn't a hormone treatment; it acts on melanocortin receptors in the brain. The best option depends on lab results, symptoms, fertility goals, and medical history.
Kisspeptin activates the reproductive hormone system and raises LH and FSH. In a 2023 trial of 32 men with low desire, an IV kisspeptin infusion increased activity in sexual brain regions and penile tumescence compared with placebo. It's still experimental and isn't approved to treat low libido.
PT-141 acts on desire and arousal through the brain rather than blood flow. Small early studies in men found a significant erectile response compared with placebo, including in some men who hadn't responded well to Viagra. It isn't FDA-approved for men, and no large trial has confirmed these results.
The most common side effects are nausea, flushing, and headache. Others include a temporary rise in blood pressure, a lower heart rate, patches of darker skin, and injection-site reactions with the injected form. Anyone with cardiovascular risk factors should consult a clinician before use.
Bremelanotide is FDA-approved as Vyleesi, an injection for acquired, generalized low sexual desire in premenopausal women. Compounded PT-141 troches, sprays, strips, and other formats are not FDA-approved.
Several telehealth platforms prescribe compounded PT-141 after an online visit with a licensed clinician. Look for one that reviews your blood pressure, heart history, and medications and uses a licensed U.S. 503A compounding pharmacy. The approved form of bremelanotide is not indicated to enhance sexual performance.
This article is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional about your health or before changing treatment. Do not delay medical care because of something you read here.
